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Abstract
The cancer stem cell hypothesis proposes that cancers arise in stem/progenitor cells through
disregulation of self-renewal pathways generating tumors which are driven by a component of “tumor
initiating cells” retaining stem cells properties. The HER2 gene is amplified in 20–30% of human
breast cancers and has been implicated in mammary tumorigenesis as well as in mediating aggressive
tumor growth and metastasis. We demonstrate that HER2 overexpression drives mammary
carcinogenesis, tumor growth and invasion through its effects on normal and malignant mammary
stem cells. HER2 overexpression in normal mammary epithelial cells increases the proportion of
stem/progenitor cells as demonstrated by in vitro mammosphere assays and the expression of stem
cell marker ALDH as well as by generation of hyperplastic lesions in humanized fat pads of NOD/
SCID mice. Overexpression of HER2 in a series of breast carcinoma cell lines increases the ALDH
expressing “cancer stem cell” population which displays increased expression of stem cell regulatory
genes, increased invasion in vitro and increased tumorigenesis in NOD/SCID mice. The effects of
HER2 overexpression on breast cancer stem cells are blocked by trastuzumab in sensitive, but not
resistant, cell lines, an effect mediated by the PI3-kinase Akt pathway. These studies provide support
for the cancer stem cell hypothesis by suggesting that the effects of HER2 amplification on
carcinogenesis, tumorigenesis and invasion may be due to its effects on normal and malignant
mammary stem/progenitor cells. Furthermore, the clinical efficacy of trastuzumab may relate to its
ability to target the cancer stem cell population in HER2 amplified tumors.
INTRODUCTION
The HER2 gene is amplified in 20–30% of human breast cancers and is associated with
aggressive metastatic disease (Slamon et al., 1987; Slamon et al., 1989). Although a number
of signaling pathways including PI3-K/Akt have been shown to be regulated by HER2, the
mechanisms by which these pathways contribute to the aggressive characteristics of these
tumors remain unclear. The humanized anti-HER2 antibody trastuzumab (Herceptin) has been
an important agent used to treat breast cancers displaying HER2 overexpression (Beuzeboc et
al., 1999). Despite its benefits, a substantial fraction of patients treated in the adjuvant setting
still relapse, one-third of patients with advanced disease fail to respond and the majority of
initial responders demonstrate disease progression within one year (Miller, 2004; Seidman et
al., 2001). The development of effective strategies for treating these trastuzumab resistant
tumors would be facilitated by a clearer understanding of the mechanisms by which HER2
overexpression induces aggressive behavior in breast cancer and the molecular mechanisms
of trastuzumab resistance.
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There is increasing evidence that a wide variety of malignancies, including breast cancer, may
be driven by a small subset of “tumor initiating cells” or “cancer stem cells” (CSC) that display
stem cell properties. Our group and others have described a subpopulation of cells in human
mammary carcinomas, with the phenotype CD44+/CD24−/lin- that display “cancer stem cell”
properties (Al-Hajj et al., 2003). These cells comprising 1–5% of primary tumors, are able to
form tumors in immunocompromised mice as well as to generate the phenotypic heterogeneity
of the initial tumor. More recently, we have reported that the stem/progenitor cell population
in both the normal mammary gland and in mammary carcinomas may also be identified by
virtue of increased expression of the enzyme aldehyde dehydrogenase as assessed by the
Aldefluor assay or by immunohistochemistry (Ginestier et al., 2007).
In addition to driving carcinogenesis, CSCs may contribute to therapeutic resistance. Indeed,
it has recently been reported that CD44+/CD24− mammary stem cells are relatively resistant
to radiation and chemotherapy in vitro and in mouse models (Phillips et al., 2006). The clinical
relevance of these observations was confirmed by the demonstration of an increase in the CSC
population following neo-adjuvant chemotherapy in patients with locally advanced breast
cancer (Li et al., 2008)
We have recently reported a significant correlation between HER2 overexpression and
expression of the stem cell marker ALDH1 in a series of 491 breast cancer patients (Ginestier
et al., 2007). Since tumorigenesis, invasion and metastasis may be mediated by the tumor stem
cell component we reasoned that the effects of HER2 overexpression on tumorigenesis might
be due to the effects of this signaling pathway on regulating the mammary stem cell population.
We report that HER2 overexpression increases the stem/progenitor cell population of both
normal and malignant mammary cells. Furthermore, the effects of HER2 overexpression on
mammary tumorigenesis and invasion are due to its effects on the CSC population. These
effects correlate with increased HER2 and Akt phosphorylation and are inhibited by
trastuzumab in sensitive but not in resistant cells. These studies indicate that HER2 signaling
regulates the mammary stem/progenitor cell population driving carcinogenesis and tumor
invasion.
RESULTS
Effects of HER2 overexpression on normal mammary stem/progenitor cells
We have previously demonstrated that normal human mammary cells generate non-adherent
spherical colonies called mammospheres (Dontu et al., 2003). These mammospheres are
composed of a small number of self-renewing cells capable of mammosphere initiation upon
serial passage, as well as a larger number of progenitor cells capable of multi lineage
differentiation (Dontu et al., 2003). To examine the role of HER2 in mammary stem cell self-
renewal, we infected normal mammary epithelial cells with lentiviruses expressing either
DsRed-HER2 or DsRed. Elevated HER2 protein levels in the HER2 lentivirus infected
compared to DsRed infected cells was confirmed by Western blotting (Figure 1A). HER2
lentivirus infected cells showed over 90% DsRed positive cells when analyzed by flow
cytometry (Supplemental Figure 1A). We have also analyzed HER2 surface expression in both
non-infected and HER2-infected NMECs by flow cytometry. Over 90% of HER2-infected
cells displayed HER2 surface expression as compared to less than 4% of non-infected NMECs
(Supplemental Figure 1B).
When DsRed or HER2 transfected cells were cultured for seven days in suspension, both the
number and size of mammospheres significantly increased in HER2 expressing normal
mammary epithelial cells (NMEC) as compared to the DsRed controls (Figure 1A). We have
previously demonstrated that the number of mammospheres generated upon serial passage
provides an indirect measure of mammary stem cell self-renewal while mammosphere size
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reflects progenitor cell proliferation. We therefore examined the ability of primary
mammospheres from both DsRed and HER2 expressing cells to form secondary and tertiary
mammospheres. The number of secondary and tertiary mammospheres generated from the
HER2 expressing cells was significantly higher than that of the control cells (Figure 1B).
HER2 overexpression expands the Aldefluor-positive cell population of normal mammary
epithelial cells in vitro and increases outgrowths in NOD-SCID mice
We previously demonstrated that normal mammary epithelial cells that express aldehyde
dehydrogenase as determined by the Aldefluor assay, display characteristics of stem/progenitor
cells. (Ginestier et al., 2007). Figure 1C shows overexpression of HER2 in normal mammary
epithelial cells increased the Aldefluor-positive population more than two-fold compared to
DsRed infected cells. The effects of HER2 overexpression on mammosphere formation and
aldehyde dehydrogenase activity may reflect direct effects of HER2 signaling on these
properties. Alternatively, HER2 overexpression may effect stem cell self-renewal producing
an increase in the stem cell population. In order to distinguish between these possibilities, we
examined the mammosphere-forming capacity of the Aldefluor-positive and -negative cells
overexpressing HER2. Only the Aldefluor-positive population was capable of mammosphere
formation in HER2 expressing cells (Figure 2A). We also demonstrated that only a small
fraction of NMECs express HER2 surface protein (Supplemental Figure 1B). Furthermore, we
observed similar HER2 surface expression in Aldefluor-positive and Aldefluor-negative
NMECs (Supplemental Figure 1C). This suggests that the effects of HER2 overexpression are
due to the generation of increased proportion of primitive mammary cells capable of
mammosphere formation.
To determine whether HER2 overexpression increased the mammosphere forming capacity of
the Aldefluor-positive population, we sorted single Aldefluor-positive cells expressing HER2
or DsRed in low attachment plates and examined the frequency of mammosphere formation.
Figure 2B demonstrates a three-fold increase in the frequency of single HER2 expressing cells
able to form mammospheres as compared to single DsRed cells. Together, these experiments
suggest that HER2 overexpression increases the mammary stem cell population and also
increases the capacity for sphere formation in this population.
We previously demonstrated that Aldefluor-positive normal human mammary cells have the
capacity to generate outgrowths in the humanized mammary fat pads of NOD-SCID mice
(Ginestier et al., 2007). We determined the effect of HER2 overexpression on mammary
outgrowths in this model. Outgrowths generated from both control and HER2 overexpressing
cells were composed of luminal and myoepithelial cells (Figure 2C). The myoepithelial cell
layer was demonstrated by smooth muscle action staining (Figure 2C). In addition, there were
areas of hyperplasia characterized by greater than an eight-fold increase in expression of the
proliferation marker KI-67 in outgrowths generated from HER2 infected compared to DsRed
cells (Figure 2C). We also tested the ability of Aldefluor-positive and Aldefluor-negative cells
overexpressing HER2 or DsRed to form mammary outgrowths. Consistent with our previous
report, only Aldefluor-positive cells produced outgrowths in this model (Table 1). Furthermore,
HER2 overexpressing Aldefluor-positive cells produced outgrowths with as few as 250 cells
(Table 1). These results are consistent with the in vitro experiments demonstrating that HER2
overexpression increases the stem cell pool as well as driving proliferation of this pool in
vivo.
HER2 overexpression increases tumorigenicity of mammary carcinomas by modulating the
stem/progenitor cell population
In order to determine the effect of HER2 overexpression on the cancer stem cell population,
we stably infected three mammary carcinoma cell lines; MCF7, SUM149, and SUM159 with
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HER2 or DsRed lentiviruses. The efficiency of infection was demonstrated by Western blotting
(Supplemental Figure 2A, B and C). HER2 overexpression resulted in a four to five-fold
increase in the Aldefluor-positive population in each of these three mammary carcinoma cell
lines (Figure 3A, Supplemental Figure 2A, B and C).
To further examine whether continued HER2 expression was required for maintenance of the
stem cell phenotype, we tested the effect of knockdown of HER2 by using a HER2 shRNA in
HCC1954 cells, a cell line which displays HER2 amplification (Finn et al., 2007). We achieved
approximately an 80% reduction in HER2 expression as assessed by Western blot utilizing this
approach (Supplemental Figure 2D). Control shRNA transfected cells contained an Aldefluor-
positive population of 6–10%, whereas knockdown of HER2 expression reduced the Aldefluor-
positive population to less than 2% (Figure 3A). These results complement the gain of function
studies and suggest that in HER2 amplified cells continued HER2 expression is required for
maintenance of the stem cell population.
To determine if the effects of HER2 overexpression on tumorigenicity occurred in all
transfected cells or was limited to stem/progenitor cells, we examined the ability of Aldefluor-
positive and negative populations to form tumors in the humanized mammary fat pads of NOD/
SCID mice. We demonstrated equal HER2 total and surface expression in Aldefluor-positive
and Aldefluor-negative cell populations (Figure 3B and Supplemental Figure 3A) Despite
equal levels of HER2 expression in Aldefluor-positive and negative SUM159-HER2 cells,
only the Aldefluor-positive cells were tumorigenic in this model (Figure 3B and C). Figure 3C
illustrates the ability of serial dilutions of Aldefluor-positive and negative populations of HER2
overexpressing cells to form tumors. As few as 500 Aldefluor-positive cells, reproducibly
formed tumors whereas only limited tumor growth was seen when up to 50,000 Aldefluor-
negative cells were injected. As was the case for MCF7-HER2 cells, we found that only the
Aldefluor-positive population of the MCF7-HER2 cells was tumorigenic (Supplementary
Figure 4A). The ability of Aldefluor-positive but not Aldefluor-negative cells to form tumors
was also demonstrated in three HER2-amplified breast cancer cell lines (Figure 3D). Similar
level of HER2 surface expression in Aldefluor-positive and Aldefluor-negative cell
populations were demonstrated by flow cytometry and immunohistochemistry (Supplemental
Figure 3B and C). The Aldefluor-positive population was not only capable of self-renewal as
demonstrated by serial transplantation, but was also able to regenerate the phenotypic
heterogeneity of Aldefluor-positive and negative populations found in the initial tumor (Figure
3B). Thus, the Aldefluor-positive-HER2-positive cell population meets the functional
definition of “cancer stem cells” in its ability to both self-renew and to differentiate regenerating
the cellular heterogeneity present in the original tumor.
To determine whether HER2 overexpression increased the tumorigenicity of the cancer stem
cell component, we examined the tumorigenicity of the Aldefluor-positive populations of
SUM159-DsRed or SUM159-HER2 cells. HER2 overexpression increased the rate of tumor
growth in Aldefluor-positive cells approximately two-fold compared to control Aldefluor-
positive cells (Supplemental 4B). Together, these results demonstrate that the effects of HER2
on tumorigenicity are due to its effects on the Aldefluor-positive cancer stem cell component.
HER2 overexpression expands this population as well as increasing its tumorigenicity.
HER2 overexpression increases invasiveness of the stem/progenitor cell population
Previous studies have demonstrated that HER2 overexpression leads to increased invasion in
in vitro matrigel assays. It has been suggested that tumor invasion and metastasis may be
mediated by the cancer stem cell population (Sheridan et al., 2006; Wicha et al., 2006). To
determine whether the effect of HER2 overexpression was due to a direct effect on tumor
invasion or alternatively was due to an increase in cancer stem cells, we tested the ability of
Aldefluor-positive and Aldefluor-negative populations of HER2 or DsRed infected MCF7 and
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Sum159 cells to invade matrigel. The Aldefluor-positive subpopulations were considerably
more invasive than Aldefluor-negative populations (Figure 4A and B). Furthermore,
overexpression of HER2 resulted in a three to six-fold increase in invasiveness in the Aldefluor-
positive populations. These results suggest that HER2 overexpression not only increases the
Aldefluor-positive stem cell component but also increases the invasiveness of this population.
HER2 overexpression induces the expression of stem cell related genes and activates the
PI3-K/Akt pathway
A number signaling pathways have been implicated in stem cell self-renewal (12). To
determine whether HER2 affected the expression of genes involved in stem cell behavior, we
examined the expression of Oct3/4, Notch1, Notch2, Jag1 and Gli1 in Aldefluor-positive and
negative populations from SUM159-HER2 or DsRed cells. Expression of these stem cell
related genes was significantly increased in Aldefluor-positive compared to Aldefluor-negative
cell populations (Figure 5A). Furthermore, there was a significant increase in the expression
of these genes in SUM159-HER2-Aldefluor-positive cells compared to Aldefluor-positive-
DsRed cells. This suggests that HER2 overexpression not only increases the stem cell pool,
but also increases the expression of stem cell related genes within this cell population.
HER2 has been shown to signal through the PI3-kinase/Akt pathway. In order to determine
the relationship between activation of this pathway and the stem cell phenotype, we examined
the levels of Akt phosphorylation by Western blot in Aldefluor-positive and -negative cell
populations isolated from control or HER2 overexpressing cell lines. Aldefluor-positive cells
showed significantly higher Akt phosphorylation compared to Aldefluor-negative cells
isolated from the same cell line (Figure 5B). Furthermore, the Aldefluor-positive population
from SUM159-HER2 showed increased levels of phospho-Akt compared to the Aldefluor-
positive population from SUM159-DsRed cells. These results were further confirmed by
phospho-Akt immunoflourescence staining of Aldefluor-positive and -negative SUM159-
DsRed and SUM159-HER2 cells (Figure 5C).
Trastuzumab decreases the Aldefluor-positive population in sensitive but not in resistant
breast cancer cells through inhibition of PI3-K Akt signaling
We examined the effect of trastuzumab on the Aldefluor-positive populations in several breast
cancer cell lines. Figure 6A (and Supplemental 5C) demonstrates that trastuzumab treatment
resulted in a greater than 80% reduction in the population of Aldefluor-positive SUM159-
HER2 cells. Interestingly, treatment of SUM159-HER2 cells decreased the Aldefluor-positive
cell population to the same level found in DsRed control cells suggesting that this antibody
inhibited HER2 signaling to baseline levels. The ability of trastuzumab to reduce the percent
of stem cells was also confirmed by immunohistochemistry utilizing an ALDH-1 monoclonal
antibody (Supplemental Figure 5D). We found approximately 50% reduction in HER2 surface
expression following trastuzumab treatement of SUM159-HER2 cells (Supplemental Figure
3A). When we analyzed whether HER2 surface expression was equally reduced in both
Aldefluor-positive and Aldefluor-negative populations, we found no significant difference in
HER2 surface expression in both populations (Supplemental Figure 3A). In order to examine
trastuzumab-induced cell death, we analyzed apoptosis following trastuzumab treatment using
Annexin V staining. Trastuzumab did not induce apoptosis in these cells as assessed by flow
cytometry (Supplemental Figure 6A).
To determine whether there was a correlation between trastuzumab’s effects on the stem cell
phenotype and cellular sensitivity to this antibody, we examined the effect of trastuzumab on
the Aldefluor-positive populations of HER2-amplified breast cancer cell lines, one HCC1954
which is trastuzumab sensitive, and MDA-MB-453 and JIMT-1 which are trastuzumab
resistant. Trastuzumab reduced the Aldefluor-positive population more than 50% in
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trastuzumab sensitive HER2 amplified HCC-1954 cells (Figure 6A). In contrast, the antibody
had no effect on the percent of Aldefluor-positive cells in the transtuzumab resistant cell lines
MDA-MB-453 and JIMT-1 (Figure 6A, Suplementary Figure 5A and B).
In order to determine whether trastuzumab resistance was associated with Akt phosphorylation,
we examined the effects of trastuzumab on Akt phosphorylation in trastuzumab sensitive and
resistant HER2 overexpressing cells. As shown in Figure 6B, trastuzumab reduced Akt
phosphorylation in the trastuzumab sensitive SUM159-HER2 cell line, but had no effect on
Akt phosphorylation in the trastuzumab resistant MDA-MB-453 cell line, which displays
constitutive Akt activation (Figure 6B).
Since HER2 activates the PI3-K/Akt pathway, we examined the effect of the PI3-K inhibitor
LY-294002 on the Aldefluor-positive population in these cell lines. Treatment of trastuzumab
sensitive and resistant cell lines with LY-294002 resulted in a significant decrease in the
Aldefluor-positive populations (Figure 6A). Furthermore PI3-K inhibitor LY294002 induced
apoptosis in 50% of cells as assessed by Annexin V staining (Supplemental Figure 6B).
Discussion
The “cancer stem cell hypothesis” proposes that cancers originate in tissue stem or progenitor
cells through disregulation of the normally tightly regulated process of self-renewal. As a
consequence cancers are composed of a cellular hierarchy with a limited number of “cancer
stem cells” capable of self-renewal driving the malignant phenotype and differentiation
generating tumor heterogeneity (Korkaya and Wicha, 2007). A frequent genetic alteration in
human breast cancer is the amplification of the HER2 gene (Slamon et al., 1987). Although
HER2 overexpression has been demonstrated to affect tumor growth, invasion and metastasis,
the mechanisms involved remain undefined. We provide evidence that the effects of HER2 on
mammary carcinogenesis, tumorigenicity and invasion result from effects of this signaling
pathway on the cancer stem cell population. Overexpression of HER2 in normal mammary
epithelial cells increases the stem/progenitor cell population as demonstrated by increased
ALDH activity and mammosphere formation in vitro and generation of hyperplastic lesions in
NOD/SCID mice. In contrast, Aldefluor-negative HER2 expressing cells neither formed
mammospheres nor produced outgrowths in humanized NOD-SCID mice.
In women, HER2 overexpression frequently occurs in premalignant lesions including atypical
ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS), suggesting that dysregulation
of HER2 signaling plays a role in tumor initiation. Our findings suggest that HER2
amplification may lead to an expansion of mammary stem cells, providing targets for further
carcinogenic events. This model could account for the demonstrated clonality of ADH and
DCIS (Allred et al., 1994; Park et al., 2006; Xu et al., 2002). HER2 overexpression may also
affect the behavior of mammary carcinomas by expanding their “cancer stem cell” populations.
We show that overexpression of HER2 in a series of human breast cancer cell lines increases
the percentage of cells with ALDH activity. The functional significance of this was
demonstrated by the ability of Aldefluor-positive/HER2 cells to form tumors which could be
serially passaged in NOD/SCID mice. Despite equivalent levels of HER2 expression in
Aldefluor-positive and negative cell populations, Aldeflour-negative cells failed to form
tumors even with 100-fold more cells. HER2 overexpression also increased the tumorigenicity
within the Aldefluor-positive population. These experiments suggest that HER2 increases the
cancer stem cell population as well as increasing tumorigenicity within this population. In
contrast, HER2 overexpression does not affect the phenotype of more differentiated Aldefluor-
negative cells.
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A number of genes and signaling pathways have been identified which regulate the self-renewal
of stem cells in a variety of developmental systems. These include Oct3/4 and genes involved
in the Notch and Hedgehog signaling pathways (Dontu et al., 2004; Liu et al., 2006; Tokuzawa
et al., 2003). We demonstrate that these genes show increased expression in Aldefluor-positive
as compared to Aldefluor-negative Sum159 cells. Furthermore, Aldefluor-positive HER2-
positive cells showed increased expression of these stem cell genes compared to Aldefluor-
positive DsRed control cells. This suggests that in addition to increasing the Aldefluor-positive
population, HER2 overexpression may also drive expression of stem cell regulatory genes
within this population. HER2 has been shown to signal through the PI3-K Akt pathway
generating a multidrug resistance phenotype (Knuefermann et al., 2003). We found that the
Aldefluor-positive cell population displayed significantly higher Akt phosphorylation than
Aldefluor-negative cells. AKT phosphorylation was further increased by HER2 overexpression
in this cell population.
A recent report suggested that the subpopulation of breast cancer cells, previously characterized
by the stem cell phenotype CD44+/CD24− (Al-Hajj et al., 2003) show higher levels of
proinvasive genes and exhibit increased invasive properties (Sheridan et al., 2006). We
demonstrate here that HER2 overexpression increases the invasiveness of both MCF7 and
SUM159 cells. Furthermore, the Aldefluor-positive populations are significantly more
invasive than the Aldefluor-negative populations. These results suggest that HER2
overexpression may have a direct effect on tumor invasion as well as an indirect effect resulting
from increases in the invasive cancer stem cell population.
In the metastatic setting, trastuzumab increases the effectiveness of chemotherapy resulting in
an increased response rate and duration of response (Burstein et al., 2001). Recent evidence
suggests that CD44+/CD24− breast cancer stem cells may be relatively resistant to both
chemotherapy and radiation. In contrast to the resistance of cancer stem cells to these
conventional treatments, our results suggest that the effectiveness of trastuzumab may be
directly related to its effects on the cancer stem cell population. A recent report demonstrating
that the HER2/EGFR inhibitor, Lapatinib when used in neoadjuvant setting decreases the
cancer stem cell component supports the clinical relevance of our findings (Li et al., 2008).
Despite the significant clinical benefits of trastuzumab, many patients treated in the adjuvant
setting still relapse and most patients with advanced disease become trastuzumab-resistant
within one year (Paik et al., 1990; Slamon et al., 1987). The development of secondary
mutations such as deletion of the tumor suppressor PTEN may contribute to trastuzumab
resistance (Nagata et al., 2004; Saal et al., 2007). We demonstrate that treatment of SUM159-
HER2 cells with trastuzumab results in an 80% reduction of the Aldefluor-positive cell
population. The effect of trastuzumab on Sum159-HER2 cells was associated with decreased
expression of phospho-HER2 and phospho-Akt. In contrast to its effect on SUM159-HER2
cells, trastuzumab had no measurable effect on phospho-HER2, phopho-Akt, or on the
proportion of the Aldefluor-positivity in two trastuzumab resistant cell lines. However, the
PI3-K inhibitor LY294002 reduced the Aldefluor-positive population in both trastuzumab
sensitive and resistant cell lines. These findings are consistent with previous reports showing
increased Akt activity in trastuzumab-resistant cell lines (Kucab et al., 2005; Tanner et al.,
2004) and suggest that the PI3-K/Akt pathway plays an important role in mediating the effects
of HER2 signaling. It is also consistent with recent reports suggesting a role for Akt signaling
in stem cell self-renewal (Welham et al., 2007) and in mediating treatment resistance (Ma et
al., 2007; Saal et al., 2007). Most recently, Berns et al. identified the PI3K pathway as a major
determinant of trastuzumab resistance in human breast tumors using a functional genomic
approach (Berns et al., 2007).
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In conclusion, our results suggest that the effects of HER2 amplification on mammary
carcinogenesis, tumorigenicity and invasion result from effects of this signaling pathway on
mammary cancer stem cells. These effects are due to the ability of HER2 to expand the stem/
progenitor cell population as well as increasing the tumorigenicity and invasiveness of this
population. Carcinogenesis may be initiated by expansion of stem cell pools which provide
targets for further carcinogenic events. Increased HER2 expression in breast cancers, in turn,
may increase the cancer stem cell component driving tumorigenesis invasion and metastasis.
An elucidation of the molecular mechanisms by which HER2 signaling drives the stem cell
pool may lead to further insights into the behavior of normal and malignant mammary stem
cells. In addition, identification of components of these pathways may lead to new targets for
cancer prevention and therapy.
Materials and Methods
Dissociation of normal mammary tissue and mammosphere assay
Mammary tissues from reduction mammoplasties was dissociated as previously described
(Stingl et al., 1998). For mammosphere experiments, single cell suspensions of NMEC were
plated on 1% agarose coated plates at a density of 1×105 and grown for 7–10 days. Subsequent
cultures after dissociation of primary spheres were plated on ultra-low attachment plates at a
density of 5×103 to 1×104. Mammosphere cultures were grown in a serum-free mammary
epithelium basal medium as previously described (Dontu et al., 2003).
Lentiviral construction and cell infections
All lentiviral constructs were prepared by the University of Michigan Vector Core facility. The
pLentiLox RSV-GFP-HER2 construct was generated by ligating the NheI & XbaI HER2
fragment from pCI-HER2 (generous gift from K. Ignatoski, Urology Medical School,
University of Michigan Ann Arbor, MI) into NheI site of pLentiLox RSV lentiviral-GFP
vector. After confirmation by restriction digestion and DNA sequencing, large scale
pLentiLox-HER2 virus was produced and used for infecting NMECs and breast cancer cell
lines. pLentiLox RSV- dsRed-HER2 vector was generated by replacing the GFP with a DsRed
insert.
Implantation of cells in NOD/SCID mice
Fat pads of three weeks old NOD/SCID mice were cleared and replaced with 1:1 mixture of
irradiated and non-irradiated human fibroblasts. Within two to three weeks, human fibroblasts
generated a humanized mammary fat pad in mice. These resulting fat pads were injected with
NMECs infected with DsRed or HER2 lentivirus. An estrogen pellet was also implanted
subcutaneously in each mouse. The mice were sacrificed after 4 to 8 weeks and the fat pads
were analyzed for outgrowths.
Breast cancer cells at serial dilutions were directly injected into the fat pads of 5 weeks old
NOD/SCID mice with an estrogen pellet implantation. The kinetics of tumor growth in these
mice were analyzed at indicated time points.
Aldefluor Assay and Flow cytometry
To measure and isolate cells with high ALDH activity, the Aldefluor assay was performed
according to manufacturer’s (Stemcell Technologies, Durham, NC) guidelines. Dissociated
single cells were suspended in Aldefluor assay buffer containing the ALDH substrate, Bodipy-
aminoacetaldehyde (BAAA) at 1,5 μM and incubated for 40 minutes at 37 °C. To distinguish
between ALDH-positive and -negative cells, a fraction of cells was incubated under identical
condition in the presence of a 10-fold molar excess of the ALDH inhibitor, diethylamino
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benzaldehyde (DEAB). This results in a significant decrease in the fluorescence intensity of
ALDH-positive cells and was used to compensate the flow cytometer.
Cell lines and HER2, DsRed lentiviral infection
MDA-MB-453 and HCC1954 cells were maintained in RPMI supplemented with 10% fetal
bovine serum and antibiotic/antimycotic (10.000 units/ml penicillin G sodium, 10.000 μg/ml
streptomycin sulfate and 25 μg/ml amphotericin B) and the JIMT-1 cells were maintained in
DMEM supplemented with 10% serum and antibiotic/antimycotic. SUM159, SUM149 and
MCF7 cells were infected with the lentivirus expressing human HER2 or control lentiviruses
expressing either GFP or DsRed. Following 12–16 hours of incubation, the viruses were
removed and replaced with fresh medium.
Immunoblotting
Cells were lysed in a laemmli buffer, boiled and loaded onto SDS-polyacrylamide gels.
Following electrophoresis, proteins were transferred onto Nitrocellulose Membranes (Pierce,
Rockford, IL) using semi dry Trans-Blot (Bio Rad Laboratories, Hercules, CA). Blots were
first incubated in TBS blocking buffer containing either 2% Milk or 2% BSA (for Phospho-
specific antbodies) for 1–2 hours at room temperature and then with the respective primary
antibodies diluted in TBST (containing 0.1%Tween20 and 2% BSA) overnight at 4°.
Subsequently, blots were washed and incubated with appropriate secondary antibodies (GE
Healthcare, UK) in TBST and detected using SuperSignal West Pico Chemiluminescent
Substrate (Pierce, Rockford, IL). Antibodies to human HER2, c-erbB-2/HER-2/neu Ab-17
(Clone e2–4001+3B5) mouse monoclonal antibody and anti-phospho-erbB-2/HER-2
(Tyr1248) antibody were from Upstate (Temecula, CA), and the phospho-Akt1 (p-Akt1/2/3
(Ser 473) antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).
Immunohistochemisty and immunofluorescent staining were carried out as described
previously (6)
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Figure 1. HER2 expression increases mammosphere formation and the Aldelfuor-positive cell
population
A. HER2 expression in normal mammary epithelial cells infected with HER2 or DsRed
lentivirus. Increased size of mammospheres in HER2 expressing cells as compared to DsRed
control. B. Serial passage of HER2 and DsRed control mammospheres. HER2 expression
increases mammosphere forming capacity upon serial passage. P values for each passage are
5.6×10−37, 8.05×10−43, 3.4×10−32 respectively. C. HER2 or DsRed cells were assessed for
ALDH activity utilizing the Aldefluor assay. HER2 expressing cells demonstrate greater than
a two-fold increase in the Aldefluor-positive cell population compared to DsRed control cells.
Insert show DEAB inhibited flow results for compensation. Data represented here are the mean
of 5 independent experiments performed in triplicates.
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Figure 2. HER2 expression increases the frequency of mammosphere formation and of ductal
structures in NOD-SCID mice
A. When plated at clonal density, only the Aldefluor-positive cells are capable of
mammosphere formation. B. A three-fold increase in mammosphere initiating single cells in
the HER2 Aldefluor-positive cell population compared to the DsRed Aldefluor-positive
population. C. Serial dilutions of HER2 or DsRed expressing NMECs were injected into the
mammary fat pads of humanized NOD/SCID mice. HER2 overexpressing cells generated an
increased number of mammary outgrowths which displayed hyperplasia (arrows) characterized
by an 8 fold increase in Ki67 staining. Myoepithelial cells were demonstrated by smooth muscle
actin (SMA) staining.
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Figure 3. Effects of HER2 overexpression on Aldefluor-positivity and tumorigenicity of human
mammary carcinoma cell lines
A. Overexpression of HER2 increased the Aldefluor-positive populations three- to five-fold
compared to control DsRed cells in indicated breast cancer cell lines. Knockdown of HER2 in
HCC1954 cells using HER2 siRNA decreased the Aldefluor-positive cell population. B.
Aldefluor-positive but not Aldefluor-negative cells display properties of tumor stem cells
despite equivalent HER2 expression in both populations as shown by Western blotting. Tumors
generated from the Aldefluor-positive population are composed of both Aldefluor-positive and
-negative populations recapitulating the initial tumor phenotype. C. Growth curves of serial
dilutions of Aldefluor-positive and -negative SUM159-HER2 cells. Aldefluor-positive cells
form tumors at all cell concentrations whereas the Aldefluor-negative cells failed to do so. D.
In HER2 amplified cell lines MDA-MB453, HCC1954 and JIMT-1, only Aldefluor-positive
cells were tumorigenic.
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Figure 4. Effects of HER2 overexpression on invasive properties of Aldelfuor-positive and -negative
populations of breast cancer cell lines
Aldefluor-positive populations from Sum159-DsRed, SUM159-HER2 (A), MCF7-DsRed or
MCF7-HER2 cells (B) showed significantly higher invasiveness compared to Aldefluor-
negative populations. Furthermore, HER2 overexpression resulted in a 5 to 6-fold increase in
the invasive potential of Aldefluor-positive cells.
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Figure 5. Expression of stem cell related genes and Akt phosphorylation
A. Aldefluor-positive cells expressed higher levels of all indicated stem cell related genes than
Aldefluor-negative cells. The expression of these genes was further elevated by HER2
overexpression. B. Aldefluor-positive populations of indicated breast cancer cell lines showed
higher Akt-phosphorylation when compared to Aldefluor-negative populations. C. Akt-
phosphorylation as assessed by immunoflourescence in Aldefluor-positive and –negative
SUM159-DsRed and SUM159-HER2 cells. Increased phospho-Akt is detected in Aldefluor-
positive and HER2 overexpressing cells.
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Figure 6. Effects of trastuzumab and LY294002 on the Aldefluor-positive population in breast
cancer cell lines
A. Trastuzumab reduced the proportion of Aldefluor-positive cells by as much as 80% in
SUM159-HER2 and HCC1954 cells. In contrast, trastuzumab had no effect on the Aldefluor-
positive population in MDA-MB-453 and JIMT-1 trastuzumab resistant cell lines. In contrast,
LY294002 reduced the proportion of Aldefluor-positive cells in all cell lines. (B) Trastuzumab
reduced phospho-HER2 and phospho-AKT expression in Sum159-HER2 cells but has no effect
on expression of these proteins in trastuzumab resistant MDA-MB-453 cells.
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